Great Basin Reports 101 U.S. Customers to End First Quarter, Reaffirms Guidance for 2015 Customer Acquisition

SALT LAKE CITY, April 13, 2015 -- Great Basin Scientific, Inc. (NASDAQ: GBSN; GBSNU), a molecular diagnostics company, today announced continued growth in the number of customers using its sample-to-result molecular diagnostic technology during the first quarter of 2015. The Company reported a total of 101 revenue-generating customers in the United States as of March 31, 2015, a 20% increase over the 84 customers reported as of the prior quarter ending December 31, 2014. Customer evaluations, which represent the Company's sales pipeline, have seen a matched increase of 20% over the fourth quarter of 2014 from 43 active and scheduled evaluations to 52 at the end of the first quarter of 2015.

"We are pleased with our momentum in converting evaluation sites into Great Basin customers," said Ryan Ashton, President and Chief Executive Officer of Great Basin Scientific. "We believe the solution we offer appeals to lab directors and technicians both for the system's ease of use and our business model which, by placing the analyzer at no cost, allows a lab to adopt molecular diagnostic testing without any capital expenditure. We're confident these underserved small-to medium-sized hospital labs will further embrace our unique product offering, and we look forward to building on this success throughout 2015. We are executing firmly against our plan to have 170 to 180 U.S. revenue-generating customers by the end of the year and another 40 to 45 sites in active and scheduled evaluations."

About Great Basin Scientific
Great Basin Scientific is a molecular diagnostics company that commercializes breakthrough chip-based technologies.  The Company is dedicated to the development of simple, yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases. The Company's vision is to make molecular diagnostic testing so simple and cost-effective that every patient will be tested for every serious infection, reducing misdiagnoses and significantly limiting the spread of infectious disease. More information can be found on the company's website at www.gbscience.com. 

Forward-Looking Statements
Certain statements in this press release may be deemed to be forward-looking statements, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding our potential future growth. Forward-looking statements involve risk and uncertainties, which could cause actual results to differ materially. These risk and uncertainties include, but are not limited to: (i) our limited operating history and history or losses; (ii) our ability to develop and commercialize new products and the timing of commercialization; (iii) our ability to obtain capital when needed; and (iv) other risks set forth in the Company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Annual Report on Form 10-K for the quarter ended December 31, 2014. These forward-looking statements speak only as of the date hereof and Great Basin Scientific specifically disclaims any obligation to update these forward-looking statements, except as required by law.

Media Contact:
Tony Russo, Ph.D. or Todd Davenport, Ph.D.
Russo Partners, LLC
212.845.4251
This email address is being protected from spambots. You need JavaScript enabled to view it.
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investor Relations Contact:
Bob Yedid
ICR
646.277.1250
This email address is being protected from spambots. You need JavaScript enabled to view it.